Q2 INTERIM REPORT APRIL - JUNE 2022
READ MORE
Mentice acquires Ankyras solutions from Galgo Medical SL
READ MORE

Mentice appoints Honeybadger as the company’s IR communication partner

Wednesday, December 4, 2019

Mentice AB (STO: MNTC), a world leader in simulation solutions for endovascular therapies, will strengthen its market communication together with the IR communication firm Honeybadger. An IR communication plan for 2020 is now being finalised, including a newsletter with in-depth information on Mentice’s business operations.

As a part of this effort, Honeybadger is appointed as Mentice’s IR communication partner in accordance with an ongoing contract. Honeybadger undertakes to assist Mentice with strategic advice as well as in the production of the company’s regulatory and non-regulatory market communication. The contract also covers an overview of relevant web solutions and the possibility to conduct PR campaigns targeted at Swedish industry and business media.

“As a company with the stated goal to become listed at the main list of Nasdaq Stockholm, it is important that we provide correct, transparent and sufficient information in our on-going dialogue with shareholders and other parties of interest. By hiring Honeybadger, we are now strengthening our resources in IR communication, which will improve our abilities to highlight all of the progress that we are constantly making within the company,” says Mentice’s CEO Göran Malmberg.

“Mentice is a leader in its field, and a pioneer when it comes to preventing medical errors by utilising innovative technology. We look forward to working with Mentice and to highlight the possibilities that the company offers in this vital field,” says Honeybadger’s CEO Johan Waldhe.

The IR communication plan that is now being finalised will be implemented gradually during the end of 2019 and the beginning of 2020.

For further information about Mentice, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610

Tel Sweden: +46 (0) 703 09 22 22

For further information about Honeybadger, please contact:
Johan Waldhe, CEO, Honeybadger
Tel: +46 (0)70 433 59 33

Email: johan.waldhe@honeybadger.se

Websites: www.honeybadger.se

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.

DELÅRSRAPPORT Q2 APRIL - JUNI 2022
LÄS MER
Mentice förvärvar Ankyras från det spanska företaget Galgo Medical S.L.
LÄS MER

Mentice appoints Honeybadger as the company’s IR communication partner

Wednesday, December 4, 2019

Mentice AB (STO: MNTC), a world leader in simulation solutions for endovascular therapies, will strengthen its market communication together with the IR communication firm Honeybadger. An IR communication plan for 2020 is now being finalised, including a newsletter with in-depth information on Mentice’s business operations.

As a part of this effort, Honeybadger is appointed as Mentice’s IR communication partner in accordance with an ongoing contract. Honeybadger undertakes to assist Mentice with strategic advice as well as in the production of the company’s regulatory and non-regulatory market communication. The contract also covers an overview of relevant web solutions and the possibility to conduct PR campaigns targeted at Swedish industry and business media.

“As a company with the stated goal to become listed at the main list of Nasdaq Stockholm, it is important that we provide correct, transparent and sufficient information in our on-going dialogue with shareholders and other parties of interest. By hiring Honeybadger, we are now strengthening our resources in IR communication, which will improve our abilities to highlight all of the progress that we are constantly making within the company,” says Mentice’s CEO Göran Malmberg.

“Mentice is a leader in its field, and a pioneer when it comes to preventing medical errors by utilising innovative technology. We look forward to working with Mentice and to highlight the possibilities that the company offers in this vital field,” says Honeybadger’s CEO Johan Waldhe.

The IR communication plan that is now being finalised will be implemented gradually during the end of 2019 and the beginning of 2020.

For further information about Mentice, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

Tel US: +1 (312) 860 5610

Tel Sweden: +46 (0) 703 09 22 22

For further information about Honeybadger, please contact:
Johan Waldhe, CEO, Honeybadger
Tel: +46 (0)70 433 59 33

Email: johan.waldhe@honeybadger.se

Websites: www.honeybadger.se

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.